WO1998006422A1 - Agents de proliferation des cellules souches hematopoietiques - Google Patents
Agents de proliferation des cellules souches hematopoietiques Download PDFInfo
- Publication number
- WO1998006422A1 WO1998006422A1 PCT/JP1997/002818 JP9702818W WO9806422A1 WO 1998006422 A1 WO1998006422 A1 WO 1998006422A1 JP 9702818 W JP9702818 W JP 9702818W WO 9806422 A1 WO9806422 A1 WO 9806422A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hematopoietic stem
- csf
- igf
- scf
- stem cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
Definitions
- the present invention relates to a hematopoietic stem cell proliferating agent and a culture method. More specifically, the present invention relates to a hematopoietic stem cell inoculating agent and a method for expanding the same, which are used alone or in combination with various colony-stimulating factor-inducing factors.
- erythropoietin EPO
- G-CSF granulocyte colony stimulating factor
- SCF stem cell growth factor
- M-CSF macrophage colony stimulating factor
- the present inventors have conducted intensive studies and found that hematopoietic stem cells were undifferentiated by using inulin-like growth factor I (IGF-I) in combination with at least one protein selected from SCF, MCSF and G-CSF. The present inventors have found that they can be sufficiently grown as they are, and have completed the present invention. Disclosure of the invention
- the present invention relates to a hematopoietic stem cell proliferating agent containing IGF-I, a hematopoietic stem cell proliferating agent comprising at least one protein selected from SCF, M-CSF and G-CSF and IGF-I.
- Hematopoietic stem cell expansion characterized in that hematopoietic stem cells are cultured in a medium containing a proliferating agent and at least one protein selected from SCF, M-CSF and G-CSF and IGF-II. Involved in the method.
- the present invention provides a method for expanding a mammalian hematopoietic stem cell comprising IGF-1 alone or 1GF-I and at least one protein selected from SCF, M-CSF and G-CSF. It is about.
- the hematopoietic stem cell proliferating agent or method of the present invention the hematopoietic stem cells can be proliferated in the body or outside the body while being undifferentiated.
- Treatment prevention of infectious diseases caused by lymphopenia, treatment of bone marrow diseases such as myelodysplasia and myelosuppression, leukemia, treatment of bone marrow diseases such as severe W disorder and bone marrow suppression, and engraftment during bone marrow transplantation It can be used for improving the engraftment rate, treating hypocytosis caused by genetic diseases, culturing hematopoietic stem cells in vitro, and in vitro culturing recombinant stem cells during gene therapy. You.
- the IGF-I used in the present invention includes a gene produced by gene synthesis technology (for example, IGF-I, see JP-A-61-1396), peptide synthesis, cell culture, and the like. And a portion of the amino acid sequence of IGF-I produced by gene recombination technology, etc. Mutant proteins having the IGF-I activity described above (for example, see the publication of W089 / 05822).
- the SCF, M-CSF or G-CSF used in the present invention includes proteins derived from human mammals such as humans and pests produced by gene recombination techniques, peptide synthesis methods, cell culture methods, and the like.
- SCF, M-CSF, or G-CSF produced by gene recombination technology, etc. have a part of the amino acid sequence of SCF, M-CSF or G-CSF substituted, inserted, added, or deleted with amino acid. Mutant proteins having CSF activity are also included.
- a sugar chain may or may not be present.
- the hematopoietic stem cell proliferating agent of the present invention uses IGF-1 in combination with SCF, M-CSF or G-CSF, these preparations and the order of administration so long as they are administered so that they coexist in the body.
- the administration route is not particularly limited.
- both or more components may be administered as a mixed preparation, or may be administered as separate preparations, either simultaneously or separately, by the same route or separate routes.
- the hematopoietic stem cell-proliferating agent of the present invention may comprise IGF-I alone or at least one protein selected from SCF, M-CSF or G-CSF, and a carrier (for example, distilled water for injection). , Physiological saline, glucose injection, etc.), stabilizers (eg, albumin, sodium citrate, arginine, dextran, etc.), pH adjusters (eg, sodium hydrogen phosphate, sodium dihydrogen phosphate, etc.) and other additives, usually oral or parenteral, such as injections, infusions, transdermals, transdermals, topical Preparations and suppositories. ⁇ ⁇
- the preparation may further contain one or more growth factors such as SCF, M-CSF, G-CSF, EPO and IL-3.
- the dose of the hematopoietic stem cell porting agent may vary depending on the patient's weight, sex, symptoms, etc .; generally, IGF-I force per adult i 1 to 1000 g / kg body weight, preferably 5 Approximately 500 / ig gZkg body weight, and when SCF, M-CSF or G-CSF are used together, SCF, M-CSF or G-CSF is the same amount as IGF-I or , 0.0: 1 to 100 times the amount.
- the route of administration of the hematopoietic stem cell inoculating agent includes oral or parenteral, for example, intravenous injection, intravenous drip injection, subcutaneous injection, coronary artery injection, transdermal, nasal, rectal administration and the like.
- IGF-I and SCF, MCSF or G-CSF may be combined in the same preparation, but are administered separately or simultaneously in separate preparations by the same or separate routes . If administered separately, whichever may be administered first.
- the hematopoietic stem cell proliferating agent of the present invention When used for the improvement of cytopenia by chemotherapeutic agents such as radiotherapy or anticancer agents, the hematopoietic stem cell proliferating agent of the present invention may be used alone, or may be further used as EPO or MPO.
- EPO chemotherapeutic agents
- MPO MPO
- CSF, SCF, IL_3 and G Can be used at the same time as CSF.
- GM-CSF or the like may be used simultaneously for the prevention of infections caused by low lymphocytes.
- bone marrow diseases such as myelodysplasia and myelosuppression
- treatment of bone marrow diseases such as leukemia, severe disability, and bone suppression
- improvement of engraftment engraftment rate during bone marrow transplantation and transmission diseases
- an appropriate growth factor such as EPO, G-CSF or GM-CSF may be used in combination, if necessary.
- growth factors can be used in combination for culturing and culturing hematopoietic stem cells in vitro, and in vitro culturing of modified stem cells during gene therapy. Cultivation of bone marrow cells in vitro is basically performed in accordance with the Neonatal Chemistry Laboratory Course 18 Cell Culture Technology (edited by The Biochemical Society of Japan, published by Tokyo Chemical Dojin, 1989). 1
- insulin transferrin, 2-methylcaptoethanol, ethanolamine, selenite and HEPES, etc.
- at least one protein selected from SCF (1 to 1000 / ig gm), M—CSF (1 to 1000 ⁇ g / m 1) and G—CSF (1 to 1000 / g / m 1) and I GF-I (1 to 100 ⁇ g Zm 1) can be added and cultured using a CO 2 incubator. Best mode for implementing
- Example 1 Obtaining hematopoietic stem cells
- Bone marrow cells were collected from the femurs of male C57BL mice (10 mice) using ⁇ - ⁇ medium (5 ml, Nikken Biomedical Research Institute). The suspension was centrifuged (1,200 rpm, 10 minutes), the supernatant was removed by suction, and the cells were suspended in ⁇ -EM medium (5 ml) containing 10% FCS. This procedure yielded approximately 3 ⁇ 10 7 bone marrow cells per mouse.
- Hematopoietic stem cells were transferred to a 96-well U-bottom microtiter plate (Nunc, Denmark) so that 50 cells / ⁇ % FCS-a-MEM ( ⁇ 1) Z well were formed.
- IGF-I mechanacenoremin, gene recombination, Fujisawa Yakuhin
- SCF protein phosphatidylcholine
- IGF-I mechanacenoremin, gene recombination, Fujisawa Yakuhin
- SCF protein phosphatidylcholine
- IGF-I should not be used in combination with SCF or M-CSF. This increases the acid phosphatase activity in the cytoplasm of the bone marrow cells fractionated in Example 2. It is known that cytosolic acid phosphatase activity corresponds to an increase in cell number. Therefore, it is clear that IGF-I shows a hematopoietic stem cell proliferation effect when used in combination with SCF or M-CSF. It is well known in the literature that SCF and M-CSF alone do not show hematopoietic stem cell proliferation effects [Okada, S. et a J. (1992) Blood 80, 3044-3050]. confirmed. Project 5 FACS
- Example 5 Each of the cells obtained in Example 5 was transferred to a 96-well plate by ACDU, and a group of about 50 ml was prepared.
- IGF-I has the effect of proliferating one hematopoietic stem cell in combination with SCF or M-CSF.
- the cultured cells were fixed on slides with acetone (203 ⁇ 4 :). Non-specific binding was suppressed with 1% BSA monophosphate buffer and treated with the antibodies shown in Table 4.
- biotinylated anti-CD3 ⁇ (clone 500 ⁇ 2) T cells
- Biotinylated anti-CDllbOtec-1) Monocyte Z macrophage Biotinylated anti-myelocytic differentiation antigen (Grl) Granulocyte
- 50 hematopoietic stem cells were transferred to a 96-well U-bottom microtiter plate (Nunc, Denmark) so as to form 50 Zl 0% FCS-a-MEM (100/1) per well.
- Human I GF-I (Mechacermin, Genetically modified, Fujisawa Pharmaceutical) (100 ng / m 1), Human G—CSF (Regulatory recombination, R & D system) (5, 50 500 mg / 1) + IGF-I (100 ⁇ g / m 1) was added, and the mixture was placed in a 37 t CO 2 incubator.
- IGF-I was used in combination with G-CSF to increase the cytosolic phosphatase activity of the bone marrow cells fractionated in Example 2.
- I have. It is known that the intracellular acid phosphatase activity has a positive correlation with the cell number. Therefore, it is clear that 1GF-I shows a hematopoietic stem cell-proliferating effect when used in combination with G-CSF. G—CSF alone, with no effect.
- Hematopoietic stem cells were transferred to a 96-well U-bottom microtiter plate (Nunc, Denmark) to make 50 cells of 10% FCS-Hi-MEM (100 ⁇ l).
- IGF-I has an effect of significantly promoting the SCF hematopoietic stem cell proliferation effect. Therefore, it is clear that it is useful for the maintenance and expansion of hematopoietic stem cells.
- a vial containing 5 ml of an aqueous solution in which various components in Table 7 are dissolved is freeze-dried to obtain a hematopoietic stem cell / abrasive.
- the use of the hematopoietic cell proliferating agent or the proliferating method of the present invention is very useful because hematopoietic stem cells can be proliferated in a body or outside a body without differentiation.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97934775A EP0953354A4 (en) | 1996-08-13 | 1997-08-12 | HEMATOPOIETIC STEM CELLS PROLIFERING ACTIVE SUBSTANCES |
US09/147,689 US6495365B1 (en) | 1996-08-13 | 1997-08-12 | Hematopoietic stem cell proliferating agents |
US10/198,355 US7037892B2 (en) | 1996-08-13 | 2002-07-19 | Hematopoietic stem cell proliferating agents |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP21364196 | 1996-08-13 | ||
JP8/213641 | 1996-08-13 | ||
JP1105497 | 1997-01-24 | ||
JP9/11054 | 1997-01-24 |
Related Child Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/147,689 A-371-Of-International US6495365B1 (en) | 1996-08-13 | 1997-08-12 | Hematopoietic stem cell proliferating agents |
US09147689 A-371-Of-International | 1997-08-12 | ||
US10/198,355 Division US7037892B2 (en) | 1996-08-13 | 2002-07-19 | Hematopoietic stem cell proliferating agents |
US10/238,738 Continuation US20030113912A1 (en) | 1996-08-13 | 2002-09-11 | Hematopoietic stem cell proliferating agents |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998006422A1 true WO1998006422A1 (fr) | 1998-02-19 |
Family
ID=26346424
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1997/002818 WO1998006422A1 (fr) | 1996-08-13 | 1997-08-12 | Agents de proliferation des cellules souches hematopoietiques |
Country Status (3)
Country | Link |
---|---|
US (3) | US6495365B1 (ja) |
EP (1) | EP0953354A4 (ja) |
WO (1) | WO1998006422A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011520224A (ja) * | 2008-05-02 | 2011-07-14 | ゼネラル・エレクトリック・カンパニイ | 電圧給電型プログラム始動式安定器 |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6495365B1 (en) * | 1996-08-13 | 2002-12-17 | Fujisawa Pharmaceutical Co., Ltd. | Hematopoietic stem cell proliferating agents |
US7320880B2 (en) | 2001-06-11 | 2008-01-22 | Nuvelo, Inc. | Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell and hematopoietic progenitor cell, and DNA coding for the same |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
KR20050042046A (ko) * | 2001-10-30 | 2005-05-04 | 다이이찌 세이야꾸 가부시기가이샤 | 조혈 줄기세포의 증식방법 |
AU2003223124A1 (en) * | 2002-04-26 | 2003-11-10 | Kirin Beer Kabushiki Kaisha | Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell or hematopoietic progenitor cell, and dna coding for the same |
WO2004042040A1 (en) * | 2002-11-08 | 2004-05-21 | Reprocell Inc. | Expansion agents for stem cells |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
US20070026485A1 (en) | 2003-04-09 | 2007-02-01 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
WO2006127896A2 (en) * | 2005-05-25 | 2006-11-30 | Neose Technologies, Inc. | Glycopegylated factor ix |
WO2005003321A2 (en) * | 2003-07-06 | 2005-01-13 | Roger Williams Medical Center | Methods of producing differentiated hematopoietic cells for treatment of cytopenia |
WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
KR101439880B1 (ko) | 2004-01-08 | 2014-09-12 | 라티오팜 게엠베하 | 펩티드의 오-결합형 글리코실화 |
EP1771066A2 (en) | 2004-07-13 | 2007-04-11 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1 |
ES2572779T3 (es) | 2004-10-29 | 2016-06-02 | Ratiopharm Gmbh | Remodelación y glucopegilación del Factor de Crecimiento de Fibroblastos (FGF) |
ES2449195T3 (es) | 2005-01-10 | 2014-03-18 | Ratiopharm Gmbh | Factor estimulante de colonias de granulocitos glicopegilado |
EP2386571B1 (en) | 2005-04-08 | 2016-06-01 | ratiopharm GmbH | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
US9187532B2 (en) | 2006-07-21 | 2015-11-17 | Novo Nordisk A/S | Glycosylation of peptides via O-linked glycosylation sequences |
EP2054521A4 (en) | 2006-10-03 | 2012-12-19 | Novo Nordisk As | METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES |
WO2009070164A1 (en) * | 2007-11-28 | 2009-06-04 | University Of Central Florida | Vigor enhancement via administration of pyrimidine derivatives |
US20080124306A1 (en) * | 2006-11-28 | 2008-05-29 | Kiminobu Sugaya | Vigor Enhancement Via Administration of Pyrimidine Derivatives |
US20080195007A1 (en) * | 2007-02-12 | 2008-08-14 | Yury Podrazhansky | Method and device for using vibroacoustic stimulaton to enhance the production of adult stem cells in living organisms |
CA2682897C (en) * | 2007-04-03 | 2016-11-22 | Biogenerix Ag | Methods of treatment using glycopegylated g-csf |
US8114668B2 (en) * | 2007-05-14 | 2012-02-14 | Cardiac Pacemakers, Inc. | Composition for cold storage of stem cells |
CN101778859B (zh) | 2007-06-12 | 2014-03-26 | 诺和诺德公司 | 改良的用于生产核苷酸糖的方法 |
US20130189239A1 (en) | 2008-02-27 | 2013-07-25 | Novo Nordisk A/S | Conjugated Factor VIII Molecules |
CA2736018C (en) * | 2008-09-16 | 2015-11-03 | Stephanie Merchant | Compositions for treating or delaying the onset of hair loss |
CA2761231C (en) | 2009-08-22 | 2021-07-13 | The Board Of Trustees Of The Leland Stanford Junior University | Imaging and evaluating embryos, oocytes, and stem cells |
CN103460038A (zh) | 2011-02-23 | 2013-12-18 | 里兰斯坦福初级大学理事会 | 检测人类胚胎中的非整倍性的方法 |
WO2013181549A2 (en) | 2012-05-31 | 2013-12-05 | Auxogyn, Inc. | In vitro embryo blastocyst prediction methods |
US10241108B2 (en) | 2013-02-01 | 2019-03-26 | Ares Trading S.A. | Abnormal syngamy phenotypes observed with time lapse imaging for early identification of embryos with lower development potential |
ES2837840T3 (es) | 2014-03-20 | 2021-07-01 | Ares Trading Sa | Medida cuantitativa de la cinética de desarrollo de la morfología de mórula y blastocisto humanos |
CN104830772A (zh) * | 2015-05-28 | 2015-08-12 | 深圳富利鑫健康产业发展有限公司 | 一种造血干细胞培养基及其应用和干细胞培养方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993009220A1 (en) * | 1991-11-06 | 1993-05-13 | Correa Paulo N | Cell culture medium |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2039209T5 (es) * | 1986-01-22 | 1996-07-16 | Chugai Pharmaceutical Co Ltd | Compuesto farmaceutico que promueve el restablecimiento de la capacidad hemopoyetica. |
CA2007886A1 (en) * | 1989-01-17 | 1990-07-17 | Marvin L. Bayne | Human insulin-like growth factor analogs with reduced binding to 28 k igf binding proteins and their production in yeast |
EP0676470A1 (en) * | 1989-10-16 | 1995-10-11 | Amgen Inc. | Stem cell factor |
US6103522A (en) * | 1994-07-20 | 2000-08-15 | Fred Hutchinson Cancer Research Center | Human marrow stromal cell lines which sustain hematopoiesis |
US6011000A (en) * | 1995-03-03 | 2000-01-04 | Perrine; Susan P. | Compositions for the treatment of blood disorders |
AU5710896A (en) * | 1995-03-31 | 1996-10-16 | Aradigm Corporation | Intrapulmonary delivery of hematopoietic drug |
US5733541A (en) * | 1995-04-21 | 1998-03-31 | The Regent Of The University Of Michigan | Hematopoietic cells: compositions and methods |
US6495365B1 (en) * | 1996-08-13 | 2002-12-17 | Fujisawa Pharmaceutical Co., Ltd. | Hematopoietic stem cell proliferating agents |
-
1997
- 1997-08-12 US US09/147,689 patent/US6495365B1/en not_active Expired - Fee Related
- 1997-08-12 WO PCT/JP1997/002818 patent/WO1998006422A1/ja not_active Application Discontinuation
- 1997-08-12 EP EP97934775A patent/EP0953354A4/en not_active Ceased
-
2002
- 2002-07-19 US US10/198,355 patent/US7037892B2/en not_active Expired - Fee Related
- 2002-09-11 US US10/238,738 patent/US20030113912A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993009220A1 (en) * | 1991-11-06 | 1993-05-13 | Correa Paulo N | Cell culture medium |
Non-Patent Citations (6)
Title |
---|
BLOOD, Vol. 86, No. 2, (1995), pages 572-580. * |
JOURNAL OF CELLULAR PHYSIOLOGY, Vol. 157, No. 1, pages 178-183. * |
ONCOGENE, Vol. 7, No. 11, (1992), pages 2243-2248. * |
See also references of EP0953354A4 * |
STEM CELLS, Vol. 15, No. 3, (1997), pages 214-222. * |
THE JOURNAL OF CLINICAL INVESTIGATION, Vol. 94, No. 1, (1994), pages 34-43. * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011520224A (ja) * | 2008-05-02 | 2011-07-14 | ゼネラル・エレクトリック・カンパニイ | 電圧給電型プログラム始動式安定器 |
Also Published As
Publication number | Publication date |
---|---|
US7037892B2 (en) | 2006-05-02 |
US20030113912A1 (en) | 2003-06-19 |
EP0953354A1 (en) | 1999-11-03 |
EP0953354A4 (en) | 2002-10-23 |
US6495365B1 (en) | 2002-12-17 |
US20030068820A1 (en) | 2003-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998006422A1 (fr) | Agents de proliferation des cellules souches hematopoietiques | |
US5199942A (en) | Method for improving autologous transplantation | |
CA2087525C (en) | Adoptive immunotherapy with interleukin-7 | |
KR100676792B1 (ko) | 수지상 세포 자극 인자 | |
KR20040023724A (ko) | 조혈 간세포의 제조법 | |
ES2409128T3 (es) | Procedimientos de mejora de anidamiento e injerto de células madre | |
US20030124091A1 (en) | Endothelial cell derived hematopoietic growth factor | |
US8247227B2 (en) | Dendritic cell precursors | |
WO2022111571A1 (zh) | 肿瘤浸润淋巴细胞培养基及其应用 | |
JPWO2003038077A1 (ja) | 造血幹細胞の増幅方法 | |
KR101027288B1 (ko) | 스탓3 활성화 줄기세포 | |
CN114891117B (zh) | 一种靶向ccr8的嵌合抗原受体t细胞及其制备方法和应用 | |
JP2021532776A (ja) | 造血細胞の遺伝子改変のための方法 | |
JPH08509859A (ja) | TGF−βの中和による長期骨髄培養物における幹細胞の拡大 | |
Wong et al. | In vivo proliferation of adoptively transferred tumor-infiltrating lymphocytes in mice | |
JPH04506818A (ja) | 造血細胞の成熟 | |
EP1150694A1 (en) | Cell composition containing macrophages, presenting anti-infectious and hematopoietic properties, and a process for preparing the same | |
KR20230128324A (ko) | 인공 다능성 줄기 세포 유래 γδ T 세포 및 그 제작방법 | |
JPH1094390A (ja) | 新規末梢血幹細胞製造法 | |
CN114686428A (zh) | 细胞-多肽偶联物及其制备方法和应用 | |
CN115975050A (zh) | 嵌合的人源t细胞受体、核酸、载体、细胞和药物组合物 | |
CN115927180A (zh) | 一种分化nk细胞的方法、培养基及其应用 | |
MXPA98002464A (en) | Dendrit cellular stimulating factor | |
JP2003289856A (ja) | 造血細胞培養用培地 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997934775 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09147689 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1997934775 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1997934775 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997934775 Country of ref document: EP |